Hiroshi Nomura, President and CEO Hisayoshi Kashima, Senior Director, Corporate Controller PLAY LIST from the beginning Q3FY2018 (April 1 to December 31, 2018)ConferenceCall Disclaimer Regarding Forward-looking Statements Financial Results for Q3 FY2018 Financial Results for Q3 FY2018 (Apr.-Dec.) -Core Basis- Revenue of Major Products in Japan Revenue of Major Products in North America & China Segment Information (Core Basis) Financial Results for Q3 FY2018 (Full Basis) Financial Forecasts for FY2018 Financial Forecasts for FY2018 (Core Basis) Status of LATUDA ANDA Litigations Status of LATUDA ANDA Litigations (U.S. Patent No.9,815,827 / 9,907,794) Research and Development Development Pipeline (as of January 2019) Clinical Development Status (Major Changes since October30, 2018)[1] Clinical Development Status (Major Changes since October30, 2018)[2] Lurasidone: Schizophrenia Phase 3 Study Results(JEWEL) SEP-363856 : Schizophrenia Phase 2 Study Results (SEP361-201) Appendices Adjustments to Core Operating Profit Activities in FY2018 : Clinical Development Status Product Launch Target (as of January 2019) Regenerative Medicine/Cell Therapy Business Plan (as of January 2019) @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Back Next